BioLineRx Ltd. (BLRX)

BioLineRx Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	28.17	42.99	51.08	57.14	22.59	27.49
Cash & Cash Equivalents	28.17	42.99	51.08	57.14	22.59	27.49
Cash Growth	-34.92%	-15.83%	-10.59%	152.96%	-17.83%	-8.83%
Receivables	3.34	1.19	0.72	0.14	0.14	0.61
Inventory	2.89	1.95	0	0	0	0
Other Current Assets	1.29	1.05	0.2	0.13	0.15	0.11
Total Current Assets	35.69	47.18	52	57.4	22.88	28.21
Property, Plant & Equipment	1.72	1.89	2.5	2.28	2.7	3.47
Goodwill and Intangibles	14.19	14.85	21.89	21.7	21.71	21.89
Total Long-Term Assets	15.91	16.74	24.38	23.99	24.41	25.36
Total Assets	51.6	63.93	76.38	81.39	47.29	53.57
Accounts Payable	8.26	10.87	6.97	5.57	5.92	7.79
Deferred Revenue	9.03	12.96	0	0	0	0
Current Debt	4.15	3.67	1.97	2.93	3.28	2.89
Other Current Liabilities	9.94	15.29	1.74	1.23	1.44	1.28
Total Current Liabilities	31.37	42.78	10.68	9.72	10.64	11.97
Long-Term Debt	7.17	7.92	10.36	1.73	4.4	7.56
Other Long-Term Liabilities	0	0	4.51	1.86	10.22	0.66
Total Long-Term Liabilities	7.17	7.92	14.86	3.59	14.62	8.22
Total Liabilities	38.54	50.7	25.54	13.3	25.26	20.19
Total Debt	11.31	11.59	12.32	4.65	7.68	10.46
Debt Growth	-12.15%	-5.95%	164.98%	-39.47%	-26.50%	19.72%
Retained Earnings	-391.3	-390.61	-329.99	-305.04	-277.99	-247.97
Comprehensive Income	-1.42	-1.42	-1.42	-1.42	-1.42	-1.42
Shareholders' Equity	13.06	13.22	50.84	68.09	22.03	33.38
Net Cash / Debt	16.86	31.4	38.76	52.48	14.9	17.03
Net Cash / Debt Growth	-44.56%	-18.98%	-26.15%	252.17%	-12.51%	-20.47%
Net Cash Per Share	0.02	0.03	0.05	0.08	0.06	0.12
Working Capital	4.32	4.4	41.32	47.69	12.24	16.24
Book Value Per Share	0.18	0.21	0.98	1.54	1.31	3.42

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).